scholarly journals Can the disease course in Parkinson’s disease be slowed?

BMC Medicine ◽  
2015 ◽  
Vol 13 (1) ◽  
Author(s):  
Amos D. Korczyn ◽  
Sharon Hassin-Baer
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Course

scholarly journals Emergencies and critical issues in Parkinson’s disease

2019 ◽  
pp. practneurol-2018-002075 ◽  
Author(s):  
Cristina Simonet ◽  
Eduardo Tolosa ◽  
Ana Camara ◽  
Francesc Valldeoriola
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Presentation ◽  
Early Recognition ◽  
Medical Intervention ◽  
Disease Course ◽  
Precipitating Factors ◽  
Critical Issues ◽  
Prompt Attention ◽  
Disease Specialist

Complications from Parkinson’s disease may develop over the disease course, sometimes unexpectedly, and require prompt or even urgent medical intervention. The most common are associated with aggravation of motor symptoms; serious non-motor complications, such as psychosis, orthostatic hypotension or sleep attacks, also occur. Here we review such complications, their clinical presentation, precipitating factors and management, including those related to using device-aided therapies. Early recognition and prompt attention to these critical situations is challenging, even for the Parkinson’s disease specialist, but is essential to prevent serious problems.

scholarly journals Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson’s Disease

2021 ◽  
Vol 15 ◽  
Author(s):  
Zubo Wu ◽  
Suyuan Wu ◽  
Tao Liang ◽  
Lin Wang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Logistic Regression ◽  
Risk Factor ◽  
Phospholipase A2 ◽  
Area Under The Curve ◽  
Diagnostic Value ◽  
Multivariable Logistic Regression Analysis ◽  
Disease Course ◽  
Clinical Value

ObjectiveTo explore the association between lipoprotein-related phospholipase A2 (Lp-PLA2) and the risk of Parkinson’s disease (PD).MethodsA case-control study involving 58 hospitalized PD patients and 60 healthy controls was carried out. Serum Lp-PLA2 level was detected. According to the disease course and severity, PD patients were subdivided to analyze the clinical value of Lp-PLA2. Relationship between Lp-PLA2 and PD risk was analyzed by logistic regression. Diagnostic value of Lp-PLA2 in PD patients was investigated using receiver’s operator characteristic curves.ResultsLp-PLA2 level was significantly higher in the PD patients compared with the controls, and was significantly and positively correlated with the Hoehn-Yahr (H&Y) stage. The serum Lp-PLA2 level and H&Y stage of PD patients with a longer disease course were significantly higher than those with a shorter disease course. PD patients with milder conditions had significantly lower serum Lp-PLA2 levels than patients with severe conditions. Multivariable logistic regression analysis indicated higher Lp-PLA2 level was an independent risk factor of PD patients. Moreover, the area under the curve for Lp-PLA2 was 0.703, which was between those of homocysteine and serum amylase A.ConclusionTo our knowledge, this is the first study to show that increased level of Lp-PLA2 is associated with the risk of PD. Lp-PLA2 may be used for early detection of PD, and provides an effective intervention target for clinical treatment of PD.

Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course

2011 ◽  
Vol 27 (3) ◽  
pp. 393-399 ◽  
Author(s):  
Núria Setó-Salvia ◽  
Javier Pagonabarraga ◽  
Henry Houlden ◽  
Berta Pascual-Sedano ◽  
Oriol Dols-Icardo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Course

scholarly journals G325R GBA mutation in Parkinson's disease: Disease course and long-term DBS outcome

2021 ◽  
Author(s):  
Claudia Ledda ◽  
Carlo Alberto Artusi ◽  
Elisa Montanaro ◽  
Tiziana Martone ◽  
Maurizio Zibetti ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Course

scholarly journals Consensus-Based Recommendations for Advance Directives of People with Parkinson’s Disease in Regard to Typical Complications by German Movement Disorder Specialists

2020 ◽  
Vol 9 (2) ◽  
pp. 449
Author(s):  
Martin Klietz ◽  
Johanna M. Berndt ◽  
Florian Wegner ◽  
Nils Schneider ◽  
Günter U. Höglinger ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Health Professionals ◽  
Delphi Study ◽  
Oral Therapy ◽  
Response Rate ◽  
Expert Panel ◽  
Evidence Based ◽  
Disease Course ◽  
Dopaminergic Therapy

A huge proportion of people with Parkinson’s disease (PwP) in Germany have written an advance directive (AD). However, the content of these forms in regard to specific Parkinson’s disease (PD)-related complications is rather low. There is an urgent need to specify ADs of PwP and consequently to improve decision-making concerning end-of-life aspects for affected patients. Evidence- and consensus-based PD-specific recommendations for ADs might help to close this gap. A Delphi study with two online Delphi rounds was initiated. Initial recommendations were built on findings from previous studies and derived from evidence-based literature. Consensus on recommendations was defined as ≥80% concordance regarding clarity of formulated aspects and relevance for clinical practice. A total of 22 experts (15.2% response rate) predominantly from the workgroup ‘neuro-palliative care’ in Germany performed two Delphi rounds. Consensus was achieved for 14 of 24 initially presented recommendations. Recommendations relating to dopaminergic therapy as well as to non-oral therapy options were considered important by the expert panel. The recommendations should be taken into account when developing and giving advice on ADs for PwP. Health professionals should be trained in counselling ADs of PwP and in integrating these recommendations in ADs during the disease course of PD.

scholarly journals Trajectories of pain over 6 years in early Parkinson’s disease: ICICLE-PD

2021 ◽  
Author(s):  
J. Naisby ◽  
R. A. Lawson ◽  
B. Galna ◽  
L. Alcock ◽  
D. J. Burn ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Symptom ◽  
Disease Course ◽  
Unexplained Pain ◽  
Nonmotor Symptom ◽  
Muscle Spasms ◽  
Early Parkinson’S Disease ◽  
Disease Questionnaire ◽  
Time Point

Abstract Introduction Pain is a common non-motor symptom in Parkinson’s disease (PD), affecting up to 85% of patients. The frequency and stability of pain over time has not been extensively studied. There is a paucity of high-quality studies investigating pain management in PD. To develop interventions, an understanding of how pain changes over the disease course is required. Methods One hundred and fifty-four participants with early PD and 99 age-and-sex-matched controls were recruited as part of a longitudinal study (Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation in PD, ICICLE-PD). Pain data were collected at 18-month intervals over 72 months in both groups using the Nonmotor Symptom Questionnaire (NMSQ), consisting of a binary yes/no response. Two questions from the Parkinson’s Disease Questionnaire (PDQ-39) were analysed for the PD group only. Results Unexplained pain was common in the PD group and occurred more frequently than in age-matched controls. ‘Aches and pains’ occurred more frequently than ‘cramps and muscle spasms’ at each time point (p < 0.001) except 54 months. Conclusions This study shows that pain is prevalent even in the early stages of PD, yet the frequency and type of pain fluctuates as symptoms progress. People with PD should be asked about their pain at clinical consultations and given support with describing pain given the different ways this can present.

scholarly journals The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II

2021 ◽  
Vol 12 ◽  
Author(s):  
José-Francisco Rocha ◽  
Georg Ebersbach ◽  
Andrew Lees ◽  
Eduardo Tolosa ◽  
Joaquim J. Ferreira ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Wide Spectrum ◽  
Motor Fluctuation ◽  
Motor Fluctuations ◽  
Disease Course ◽  
Treatment Pathway ◽  
Levodopa Treatment ◽  
Post Hoc ◽  
Off Time

Introduction: Opicapone (OPC) was efficacious in reducing OFF-time in two pivotal trials in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (BIPARK-I and -II). Post-hoc analyses of these trials evaluated the efficacy of OPC following pre-defined segmentation of the wide spectrum of motor fluctuations in PD.Methods: Data from matching treatment arms in BIPARK-I and -II were combined for the placebo (PLC) and OPC 50-mg groups, and exploratory post-hoc analyses were performed to investigate the efficacy of OPC 50 mg vs. PLC in subgroups of patients who were in “earlier” vs. “later” stages of both their disease course (e.g., duration of PD &lt;6 years vs. ≥6 years) and levodopa treatment pathway (e.g., number of daily levodopa intakes &lt;4 vs. ≥4). Efficacy variables included changes from baseline in absolute OFF-time and total ON-time.Results: The Full Analysis Set included 517 patients (PLC, n = 255; OPC 50 mg, n = 262). OPC 50 mg was significantly more effective than PLC in reducing OFF-time and increasing ON-time in the majority of subgroup analyses (p &lt; 0.05). Moreover, patients in “earlier” stages of both their disease course and levodopa treatment pathway experienced numerically greater efficacy when using OPC 50 mg, in comparison with those in “later” stages.Conclusion: OPC 50 mg was efficacious over the whole trajectory of motor fluctuation evolution in PD patients. There was also a signal for enhanced efficacy in patients who were earlier vs. later in their disease course and levodopa treatment pathway.

scholarly journals Biomarker in Parkinson’s Disease: Clinical and Biochemical Biomarker

2021 ◽  
Vol 39 (4) ◽  
pp. 287-297
Author(s):  
Ju-Young Lee ◽  
Hyeo-il Ma ◽  
Young Eun Kim
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disease ◽  
Biological Tissue ◽  
Disease Course ◽  
Prodromal Stage ◽  
Successful Development ◽  
Disease Modifying Therapy ◽  
Clinical Biomarkers ◽  
Disease Modifying

Parkinson’s disease is a neurodegenerative disease compromising progressive motor and non-motor features for a long disease course. Although many drugs controlling parkinsonian symptoms were discovered, treatment with disease-modifying or halting effect was not developed to date. The exploration of reliable biomarkers would be helpful for better predicting disease progression and thereby successful development of disease-modifying therapy. In this review, we will review the clinical biomarkers in the prodromal stage and biomarkers using biological tissue in Parkinson’s disease.

Sign in / Sign up

Export Citation Format

Share Document